Laurel Wealth Advisors (California)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,217	Closed	-$424K	–	788
2021 Q3	$424K	Buy	4,217 +250	+6%	+$29.3K	0.08%	268
2021 Q2	$561K	Buy	3,967 +50	+1%	+$5.65K	0.07%	258
2021 Q1	$391K	Buy	3,917 +1,475	+60%	+$172K	0.06%	300
2020 Q4	$302K	Buy	+2,442	New	+$321K	0.04%	331

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Laurel Wealth Advisors (California)'s RETA Position: Q4 2021 in Review

Laurel Wealth Advisors (California) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 4,217 shares — an estimated $424K sold.

Laurel Wealth Advisors (California) first reported a position in RETA in Q4 2020 and held it in 4 quarters. The position peaked at $561K in Q2 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Laurel Wealth Advisors (California) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Laurel Wealth Advisors (California) sold 4,217 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $424K.
Laurel Wealth Advisors (California) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 4 quarters.
Laurel Wealth Advisors (California)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $561K in Q2 2021.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2021, filed 14 Feb 2022.